Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Leukemia|February 23, 2018
ANP32A regulates histone H3 acetylation and promotes leukemogenesisXuejing Yang, Bin Lu, Xueqin Sun, et al.
Advances in Therapy|May 3, 2025
Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up AnalysisLijuan Deng, Yuqin Song, Keshu Zhou, et al.
Clinical and Translational Medicine|September 27, 2022
CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutationsLing Tang, Hongming Huang, Yutong Tang, et al.
Experimental Hematology & Oncology|August 26, 2025
Improving CAR-T cell function through a targeted cytokine delivery system utilizing car target-modified extracellular vesiclesYuanyuan Zhang, Meijuan Huang, Shujia Zhang, et al.
Frontiers in Immunology|May 16, 2022
T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell LymphomaJiachen Wang, Kefeng Shen, Wei Mu, et al.
Plos One|August 3, 2016
Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective AnalysisYi Li, Jia Wei, Xia Mao, et al.
Cancer Medicine|September 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysisYuqin Song, Keshu Zhou, Dehui Zou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2024
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I StudyYuqin Song, Zhengming Jin, Zhi-Ming Li, et al.
British Journal of Haematology|June 1, 2026
Clinical profiling and outcomes of ischaemic stroke patients with immune thrombocytopenia: A multicentre retrospective studyLiQin Cao, Jin Wu, ZhuoYu An, et al.
Hematology (Amsterdam, Netherlands)|August 24, 2022
Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational studyHongsheng Zhou, Qingsong Yin, Jie Jin, et al.
Pageof 9